Wilmington, Delaware, United States Incyte is the famous Corporate Investor, which was founded in 1991. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Wilmington.
Among the most popular fund investment industries, there are Pharmaceutical, E-Learning. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Iconix Biosciences. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Incyte, startups are often financed by Prelude Trust, Avlar BioVentures. The meaningful sponsors for the fund in investment in the same round are Wilson Sonsini Goodrich & Rosati, The Cambridge Gateway Fund, Roche Venture Fund. In the next rounds fund is usually obtained by IVP (Institutional Venture Partners).
Comparing to the other companies, this Incyte performs on 38 percentage points more the average number of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2007. The important activity for fund was in 2002. The fund is constantly included in less than 2 investment rounds annually.
Related Funds
| Fund Name | Location |
| 8 Miles | England, London, United Kingdom |
| Dos Rios Partners | Austin, Texas, United States |
| First Angel Network | Canada, Halifax, Nova Scotia |
| Huron River Ventures | Ann Arbor, Michigan, United States |
| Richland Investments | Houston, Texas, United States |
| Tellus Partners | Salt Lake City, United States, Utah |
| UNIT4 | Netherlands, Utrecht, Utrecht |
| Western & Southern Financial Group | Cincinnati, Ohio, United States |
| Zhong Ying Touzi | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
De Novo Pharmaceuticals | $23M | 26 Jul 2001 | Cambridge, England, United Kingdom | ||
GeneEd | $2M | 26 Jun 2000 | San Francisco, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
De Novo Pharmaceuticals | $23M | 26 Jul 2001 | Cambridge, England, United Kingdom | ||
GeneEd | $2M | 26 Jun 2000 | San Francisco, California, United States |
